Heterocyclic Compounds

Matches 401 - 450 out of 30,793	< 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 >

Document	Document Title
WO/2023/155710A1	IKZF2 DEGRADATION AGENT, PHARMACEUTICAL COMPOSITION COMPRISING SAME AND USE THEREOF The present invention belongs to the field of medicinal chemistry, and relates to an IKZF2 degradation agent, a pharmaceutical composition comprising same and use thereof. Specifically, the IKZF2 degradation agent has a structure represe...
WO/2023/159155A1	INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) AND USES THEREOF Disclosed herein are compounds of Formulae 1A, 1B, 1C and 1D, (1A), (1B), (1C) and (1D) and methods of making and methods of using the same.
WO/2023/156863A1	PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF Provided is an inhibitor of AXL, Mer, and/or c-Met of Formula (I) or a pharmaceutically acceptable salt thereof: Formula (I), in which R1, R2, R3, G, and Q are described herein. Further provided is a method of treating or preventing an A...
WO/2023/155927A1	INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF The present disclosure provides an inhibitor, represented by formula I, of interaction between YAP/TAZ and TEAD, preparation thereof, a pharmaceutical composition thereof and use thereof. The compound provided in the present disclosure c...
WO/2023/155912A1	RECYCLABLE HIGH-REACTIVITY HYPERVALENT IODINE REAGENT The present invention provides a recyclable hypervalent iodine reagent having a high reactivity. Specifically, the invention provides a hypervalent iodine reagent capable of realizing high-selectivity coupling, and a method for preparing...
WO/2023/154426A1	CDK INHIBITORS AND METHODS OF USE THEREOF The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of CDK enzymes with the compounds and compositions of the disclosure. The present disclosure further relat...
WO/2023/151660A1	CRYSTALLINE FORM OF P2X3 RECEPTOR ANTAGONIST, AND PREPARATION METHOD THEREFOR The present disclosure relates to a crystalline form of a P2X3 receptor antagonist and a preparation method therefor. Specifically, the present disclosure provides a crystalline form of a compound (S)-1-(4-(1-((4-acetylmorpholin-2-yl) me...
WO/2023/154466A1	ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF Arylbenzoisoxazole compounds of Formula (II), where R1 and R2 are defined herein, are useful for inhibiting isoforms of IP6K and IPMK, and for treating diseases and disorders such as non-alcoholic fatty liver disease (NAFLD), non-alcohol...
WO/2023/154417A1	MORPHIC FORMS OF CFT7455 AND METHODS OF MANUFACTURE THEREOF An advantageous morphic form of Compound (1) which is also known as CFT7455 and is (S)-3-(6-(4-(morpholinomethyl)benzyl)-2-oxobenzo[cd]indol-l( 2H)-yl)piperidine-2, 6-dione and methods to prepare Compound (1) for therapeutic applications...
WO/2023/151575A1	HETEROCYCLIC GLP-1 AGONISTS Provided are GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.
WO/2023/152349A1	IRAK4 INHIBITORS The present application relates to chemical compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and consequently have potential utility in medicine.
WO/2023/154499A1	EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.
WO/2023/151658A1	PHARMACEUTICALLY ACCEPTABLE SALT OF P2X3 RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR The present disclosure relates to a pharmaceutically acceptable salt of a P2X3 receptor antagonist and a preparation method therefor. Specifically, the present disclosure provides a pharmaceutically acceptable salt of a compound (S)-1-(4...
WO/2023/151574A1	HETEROCYCLIC GLP-1 AGONISTS The present disclosure relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.
WO/2023/152042A1	ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES A series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives, substituted in the 6-position by an arylphenyl or heteroarylphenyl moiety, being potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in h...
WO/2023/154519A1	INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Provided are compounds of the Formula (I); or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
WO/2023/154310A1	2-METHYL-4-PHENYLPIPERIDIN-4-OL DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharma...
WO/2023/150236A1	METHODS OF PREPARING AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZAT RICYCLO[ 12.3.1.12,5]NONADECA-1(18),2,4,14,16-PENTAEN-6-OL Processes and methods of preparing Compound (I) are disclosed. Crystalline forms of Compound (I), pharmaceutically acceptable salts, solvates, hydrates, and cocrystals thereof, pharmaceutical compositions comprising the same, methods of ...
WO/2023/150526A1	COMPETITIVE AND NONCOMPETITIVE OCTAHYDROCYCLOPENTA[C]PYRROLE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 Arylsulfonamides of 5-substituted octahydrocyclopenta[c]pyrroles, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatr...
WO/2023/150592A2	N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS A compound of Formula (I) or a pharmaceutically acceptable salt thereof, is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.
WO/2023/148501A1	HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS The present invention relates to compounds of formula (I) that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to p...
WO/2023/150591A2	PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS A compound of Formula (I) or a pharmaceutically acceptable salt thereof, is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.
WO/2023/144764A1	BENZOISOTHIAZOLE AND BENZOISOXAZOLE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS The present invention relates to substituted heterocyclic compounds represented by the general formula (I), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof. The present invention also describes the me...
WO/2023/069514A9	BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY This disclosure relates to compounds of formulae I, II and III useful for degrading ITK via a ubiquitin proteolytic pathway. This disclosure also provides pharmaceutically acceptable compositions comprising said compounds, and methods of...
WO/2023/142214A1	3-HYDROXY-5-(ISOXAZOL-5-YL) PYRIDINE FORMYLGLYCINE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE A series of 3-hydroxy-5-(isoxazol-5-yl) pyridine formylglycine compounds, a preparation method, a pharmaceutical composition, and the use. A structure of the compounds is shown as formula (I), and the compound derivatives comprise pharma...
WO/2023/146785A1	PYRROLIDINE COMPOUNDS The present disclosure provides compounds of the formula (III) and their pharmaceutically acceptable salts, and compounds of the formula (IV) and their pharmaceutically acceptable salts, and pharmaceutical compositions comprising these c...
WO/2023/145804A1	NOVEL B0AT1 INHIBITOR The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
WO/2023/145962A1	PHOTOCHROMIC COMPOUND, PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND EYEGLASSES The present invention provides a photochromic compound expressed by general formula 1. In general formula 1, R represents an unsubstituted aliphatic monocycle having at most six carbon atoms (including the carbon atom at position 13 of t...
WO/2023/144793A1	POL THETA INHIBITORS The present invention relates to compounds of formula (I), that possess DNA polymerase theta (POLQ) enzyme inhibitory activity, methods for their preparation, pharmaceutical compositions containing them, and their use in the treatment or...
WO/2023/143354A1	TRICYCLIC COMPOUND AND APPLICATION THEREOF The present invention relates to a tricyclic compound represented by formula (O), a pharmaceutical composition comprising the compound as an active ingredient, and an application thereof. The compound is an excellent TEAD inhibitor and c...
WO/2023/143389A1	FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL APPLICATION THEREOF The present disclosure relates to a fused heterocyclic compound, a preparation method therefor, and a medical application thereof. Specifically, the present disclosure relates to a fused heterocyclic compound represented by general formu...
WO/2023/142641A1	PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF Provided are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, a preparation method for the compound and a use thereof in preparation of drugs for...
WO/2023/144160A1	NEW HETEROCYCLIC COMPOUNDS The invention provides new heterocyclic compounds having the general formula (I) wherein A and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the comp...
WO/2023/143623A1	QUINOLINE COMPOUND AND USE THEREOF Disclosed are a quinoline compound and the use thereof. The quinoline compound is a compound as represented by formula (I), formula (II) or formula (III), a pharmaceutically acceptable salt thereof, a solvate thereof, a stereoisomer ther...
WO/2023/143112A1	SALT FORM AND CRYSTAL FORM OF AZABENZO EIGHT-MEMBERED RING COMPOUND AND APPLICATION THEREOF Disclosed are a salt form and a crystal form of an azabenzo eight-membered ring compound and an application thereof. Specifically disclosed are a crystal form A, crystal form B, crystal form C, and crystal form D of fumarate salt, hydroc...
WO/2023/141852A1	CDK2 INHIBITORS, PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed are compounds represented by formula 1a or formula 1b, and respective optical isomers, prodrugs, or pharmaceutically acceptable salts, and pharmaceutical compositions thereof, and the use thereof in the preparation of CDK2 inhi...
WO/2023/142231A1	PREPARATION METHOD FOR C3-ALKYLATED INDOLE A preparation method for C3-alkylated indole, in which elemental iodine is used as a catalyst, silane is used as a reducing agent and a carbonyl compound is used as an alkylation reagent, and the C3-alkylated indole is prepared under mil...
WO/2023/144733A1	COMPOUNDS AND PROCESSES FOR THE PREPARATION OF ERIBULIN The present invention relates to compounds and a process for the preparation of eribulin. More specifically, the process to prepare the C14- C35 sulfone fragment of eribulin (i.e. compounds of formula I) by reacting a C14-C26 ketone frag...
WO/2023/147418A1	PARP7 INHIBITORS Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, togeth...
WO/2023/145963A1	PHOTOCHROMIC COMPOUND, PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND EYEGLASSES The present invention provides a photochromic compound expressed by general formula 1. In general formula 1, R represents a ring structure that is spiro-fused to a indeno-fused naphthopyran, said structure being a substituted or unsubsti...
WO/2023/140709A1	OXAZOLE DERIVATIVE COMPOUND HAVING ANTIBACTERIAL ACTIVITY AND MEDICAL USE THEREOF The present disclosure provides a novel oxazole derivative compound having anti-Mycobacterium tuberculosis activity or a pharmaceutically acceptable salt thereof. The present disclosure also provides an antibacterial composition comprisi...
WO/2023/138583A1	HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF Provided in the present invention are a heterocyclic compound, a pharmaceutical composition and the use thereof. Specifically disclosed are a heterocyclic compound as represented by formula (I-0), a pharmaceutically acceptable salt or st...
WO/2023/139085A1	NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES The invention relates to a compound of formula (I) wherein A1, A2, A3, R1, R2, R2', R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
WO/2023/141225A1	FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as neurological disorders. Pharmaceutical compositions and methods of making various azaindole and benzisoxazo...
WO/2023/139199A1	COMPOUNDS AND THEIR USE IN TREATING CANCER Compounds of Formula (I) or a pharmaceutically acceptable salt thereof are PROTAC compounds useful in the treatment of prostate cancer.
WO/2023/140649A1	NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present specification relates to a compound represented by chemical formula 1 and to an organic light-emitting device comprising: a first electrode; a second electrode; and one or more organic material layers provided between the fir...
WO/2023/138612A1	HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS Disclosed herein are compounds of Formula (I) : or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activity of hematopoietic progenitor kinase (HPK1), and...
WO/2023/136595A1	ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME The present invention is directed to an organic compound employed in an organic layer, such as a hole transport layer, in an organic light emitting device, wherein the organic compound has a lower refractive index than conventional hole ...
WO/2023/136295A1	PYRIMIDINE COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT One purpose of the present invention is to provide a compound which is suitable for use as a material for a capping layer in an organic EL element, has a high refractive index in a wavelength range from 450 nm to 750 nm, and has a low ex...
WO/2023/134752A1	DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR The present invention provides a diaryl compound as a tubulin/Src dual target inhibitor. The present invention also provides a diaryl compound represented by formula I, a tautomer, a stereoisomer, a solvate, a pharmaceutically acceptable...

Matches 401 - 450 out of 30,793	< 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 >